137 related articles for article (PubMed ID: 38695552)
1. Clonotypic VDJ rearrangements in Mixed Phenotype Acute Leukemia can be Successfully Utilized to Track Minimal Residual Disease (MRD).
Hennawi M; Quadeer F; Pakasticali N; Osman S; Tashkandi H; Hussaini MO
Appl Immunohistochem Mol Morphol; 2024 May; ():. PubMed ID: 38695552
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
6. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
Momen N; Tario J; Fu K; Qian YW
J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape of Mixed-Phenotype Acute Leukemia.
Hennawi M; Pakasticali N; Tashkandi H; Hussaini M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232559
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
10. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
11. A Cost Impact Analysis of clonoSEQ
Walzer S; Krenberger S; Vollmer L; Hewitt T; Eckert B
Oncol Ther; 2021 Dec; 9(2):607-619. PubMed ID: 34480748
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
13. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia.
Lee JW; Kim Y; Ahn A; Lee JM; Yoo JW; Kim S; Cho B; Chung NG; Kim M
Front Oncol; 2022; 12():957743. PubMed ID: 36185293
[TBL] [Abstract][Full Text] [Related]
16. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
van der Velden VH; Szczepanski T; Wijkhuijs JM; Hart PG; Hoogeveen PG; Hop WC; van Wering ER; van Dongen JJ
Leukemia; 2003 Sep; 17(9):1834-44. PubMed ID: 12970784
[TBL] [Abstract][Full Text] [Related]
17. Novel analysis of minimal residual disease in leukemia with TCR beta rearrangement--detection of monoclonality by single strand conformation polymorphism and PCR using a clonotype primer of leukemic T cell receptor beta-chain RNA.
Hanawa H; Koike T; Sakaue M; Kishi K; Shibata A; Abo T
Leuk Res; 1997 Mar; 21(3):201-10. PubMed ID: 9111164
[TBL] [Abstract][Full Text] [Related]
18. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]